The Latest Breaking News from Merck

Merck's ovarian cancer trial met its primary endpoint, while lymphoma trial data set the Phase 3 dose for zilovertamab vedotin at 1.75 mg/kg.

Merck has underperformed the pharmaceuticals industry over the past year, but analysts are highly optimistic about the stock’s prospects.

Deep-pocketed investors have adopted a bearish approach towards Merck Co (NYSE:MRK), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MRK usually suggests something big is…

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today positive topline results from the Phase 3 ZENITH study evaluating WINREVAIR (sotatercept-csrk) in adults with pulmonary arterial

Despite Merck & Co.’s underperformance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

'We fear a second Trump term would be bad for business and the U.S. economy.'

These companies have faced setbacks, but I'm confident their stock prices will flourish once again.

More than 41,000 people in the U.S. died of pneumonia in 2022, according to the CDC.

"It is integrated into everything that we do," says Merck's chief information and digital officer Dave Williams.

Merck & Co. is projected to report its third-quarter earnings result at the end of this month, and analysts expect a double-digit profit dip.

Patient groups should be playing a central role in Canada’s health-care system, advocating for their members by promoting the visibility of their conditions, pushing for more rapid and accurate diagnoses and lobbying for the introduction and funding of new treatments and drugs that may help relieve their members’ symptoms and…